Drug Profile
Alpha-1 antitrypsin gene therapy
Alternative Names: Alpha-antitrypsin gene therapyLatest Information Update: 14 May 2001
Price :
$50
*
At a glance
- Originator Vanderbilt University
- Developer Valentis; Vanderbilt University
- Class Gene therapies
- Mechanism of Action Trypsin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis; Emphysema; Respiratory syncytial virus infections
Most Recent Events
- 14 May 2001 Discontinued-I for Emphysema in USA (Inhalation)
- 14 May 2001 Discontinued-Preclinical for Respiratory syncytial virus infections in USA (Unknown route)
- 14 May 2001 Discontinued-Unspecified Phase in Cystic fibrosis in USA (Inhalation)